Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.6118143459915613 | N/A |
Market Cap | $118.22M | N/A |
Shares Outstanding | 193.23M | 29.26% |
Employees | 9.00 | N/A |
Shareholder Equity | -844.00K | -364.58% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -20.39 | N/A |
P/B Ratio | -140.07 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 5.2409 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$4.42M | N/A |
EPS | -0.03 | N/A |
Earnings Yield | -0.049 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $723.63K | N/A |
Cash on Hand | $568.21K | N/A |
Debt to Equity | -1.5606 | -120.75% |
Current Ratio | 0.5315 | -50.92% |